InterCure Ltd. (Tel-Aviv Stock Exchange: INCR), a medical device company, is successfully selling the world's first, FDA-cleared, non-drug, non-invasive hypertension treatment device RESPeRATE.®
InterCure has an exciting product pipeline based on its broadly-patented “Device-Guided Breathing” technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
Headquartered from New York, NY and Lod Israel, InterCure is a publicly traded Israeli company founded in 1994 by Dr. Benjamin Gavish and Erez Gavish. InterCure also operates a marketing office in London, outsourced call centers/warehouses in NJ, Southampton, UK and Saskatchewan, Canada.
RESPeRATE Customer Facts
90% of RESPeRATE owners are satisfied with the device and are still using it regularly after eight to twelve weeks.
Two-thirds of owners would definitely recommend RESPeRATE to a friend.
Already 20% of primary care physicians in the US are aware of RESPeRATE. 6 out of 10 of these physicians recommend the product.
90% of RESPeRATE owners are over the age of 50 (equally male and female).
2/3 of RESPeRATE owners are on medications, most of whom suffer from side effects and almost all of whom have previously tried diet and exercise to lower their blood pressure.
Source: Ipsos-Vantis market research and on file information
Corporate Milestones
2008
InterCure signs agreement with Boots UK Limited, the largest pharmacy chain in the UK, for the distribution of the RESPeRATE.
RESPeRATE Ultra is launched, the company's "smartest" blood pressure treatment device, just half the size of previous models featuring an interactive tutorial.
Journal of Human Hypertension publishes study demonstrating RESPeRATE's effectiveness in lowering blood pressure for diabetic hypertensive patients.
InterCure Ltd receives Deloitte Technology Fast 50 and Fast 500 Award.
Circulation: Heart Failure publishes RESPeRATE clinical study results.
Warehouse club distribution begins through Costco.com.
Nationwide retail pharmacy distribution begins at Lloyds Pharmacy in UK.
Initial distribution begins at CVS Home Health Centers in 8 states.
Ranked No. 1 website by visits among all US Pharmaceutical and Medical Products (Hitwise Health and Medical survey Q1 2008).
RESPeRATE attains its 100,000th user.
2007
InterCure names Scot Dube Vice President of Sales.
InterCure, Ltd receives Deloitte Technology Fast 50 and Fast 500 Award.
InterCure and High Tech Health announce RESPeRATE launch into pharmacy market in Australia.
InterCure and Mashco announce launch into independent pharmacies in the United Kingdom.
InterCure and Omron Healthcare (UK) Ltd. announce marketing collaboration for hypertension market in United Kingdom.
On July 26th 2007, InterCure completed its IPO on the Tel Aviv Stock Exchange and raised $16M in common shares and convertible bonds (TASE: INCR).
California Technology Assessment Forum (CTAF), a program of the Blue Shield of California Foundation, finds RESPeRATE meets its safety and effectiveness criteria.
10th clinical study finds RESPeRATE effective in lowering blood pressure for diabetic hypertensives.
2006
InterCure expands its direct-to-consumer operation in the UK; Print advertising campaign begins in over 100 daily newspapers in the UK and the US.
RESPeRATE attains its 50,000th user.
Website becomes the most popular hypertension destination.
RESPeRATE Duo™ introduced allowing two users to track progress in separate memories (on a single device).
Distribution agreement for RESPeRATE in Japan.
Medscape's peer reviewed paper, Med Gen Med, publishes a clinical review of RESPeRATE's seven clinical studies. Eighth & ninth clinical studies confirm RESPeRATE's efficacy in Asians and in the diabetic hypertensive population.
2005
InterCure awarded Hypertension Treatment Technology Innovation of the year by Frost & Sullivan.
InterCure focuses on online marketing to promote RESPeRATE in a cost effective manner; Series C investment round secured.
2004
10,000 satisfied users; Wall Street Journal & Washington Post rave about RESPeRATE.
Korean FDA and other key markets clear RESPeRATE.
2003
RESPeRATE begins selling in the US; Limited funding hinders on product launch.
Seventh study demonstrates RESPeRATE's therapeutic powers in resistant hypertensive patients.
2002
FDA clears RESPeRATE for OTC use following successful US-based, multi-center, randomized controlled study (study #6).
2001
Fourth and fifth clinical studies successfully demonstrate RESPeRATE's efficacy in lowering blood pressure when measured with 24-ambolutory and/or home blood pressure monitors.
Series B funding secured.
Scientific Advisory Board is established.
2000
FDA clears RESPeRATE as a hypertension treatment device under doctors prescription (Rx), based on successful results of three randomized controlled studies.
InterCure Inc., commences operation in NY after Series A funding is secured.
1997
InterCure commences operations after seed financing secured.
Dr. Mallika Marshall interviews Terry Moser and her doctor, Guy Pugh.
RESPeRATE Scientific Advisory Board
Our Scientific Advisory Board includes past Presidents of the American, European and International Societies of Hypertension, as well as other key cardiovascular opinion leaders:
Please Note: RESPeRATE should only be used as a part of an overall health program for achieving goal blood pressure, as recommended by a doctor. RESPeRATE can be safely used in conjunction with medications and lifestyle modifications such as diet and exercise.
